A 62-year-old guy from Gerguy won 217 Covid vaccinations and all was well

To review this article, select My Profile and then View Saved Stories.

Beth Mole, Ars Technica

In Gerguyy, a 62-year-old man objected to getting vaccinated against Covid-19 217 over a 29-month period, for “private reasons”. But, surprisingly, he does not appear to have suffered the adverse effects of overvaccination. , according to a case study recently published in The Lancet Infectious Diseases.

Of course, this is only one person, so the effects cannot be extrapolated to the general population. But they run afoul of a widespread fear among researchers that such overexposure to vaccination may simply lead to a weaker immune response. Some experts have raised this fear during discussions about how other people deserve to get Covid-19 boosters.

This story made its way to Ars Technica, a trusted source for tech news, tech policy analysis, reviews, and more. Ars is owned by WIRED’s parent company, Condé Nast.

In the case of chronic exposure to a pathogenic germ, “it appears that certain types of immune cells, called T cells, become fatigued, causing them to release fewer pro-inflammatory messenger substances,” according to study co-leader Kilian Schober. of the Institute of Microbiology – Clinical Microbiology, Immunology and Hygiene. This, along with other effects, can lead to “immune tolerance” that leads to weaker and less effective responses to fight a pathogen, Schober explained in a news release.

Gerguy’s excessive history of hypervaccination seemed like a smart case to look for evidence of such tolerance and weaker responses. Schober and his colleagues learned of the man’s case from the headlines: Authorities had opened a fraud investigation against the man, confirming 130 vaccinations over the course of nine months, but no fees were ever charged. “So we got in touch with him and invited him to conduct tests in Erlangen [a city in Bavaria],” Schober explained. “I was very interested in doing it. ” The man then informed the researchers of 87 additional vaccines, which included a total of eight other vaccine formulations, adding up to updated boosters.

The researchers were required to collect blood and saliva samples from humans between doses 214 and 217 of the vaccine. They compared their immune responses with those of 29 other people who won a popular three-dose series.

Despite the dizzying number of vaccines, humans have never reported any side effects from the vaccine, and their clinical trials have revealed no abnormalities similar to overvaccination. The researchers looked in detail at their responses to the vaccines and found that while some facets of their coverage were stronger, overall, their immune responses were functionally similar to those of other people who gained far fewer doses. The levels of vaccine-induced antibodies in their blood increased after another dose, but then began to decline, similar to what they observed in controls.

The ability of their antibodies to neutralize SARS-CoV-2 appeared to be five to eleven times greater than that of controls, but the researchers noted that this was due to a higher number of antibodies and not more potent antibodies. The number of immune cells, i. e. , B cells trained against the SARS-CoV-2 spike protein and effector T cells, increased compared to controls, but appeared to function normally. As another type of control, the researchers also looked at the human immune reaction to an unrelated virus, Epstein-Barr, which causes mononucleosis. They found that rampant vaccinations did not have a negative effect on reactions to this virus, suggesting that there were no adverse effects on immune reactions overall.

Finally, several types of evidence indicated that humans had never been inflamed with SARS-CoV-2, but the researchers were careful to point out that this could simply be due to other precautions humans have taken beyond administering 217 vaccines.

“In summary, our case report shows that hypervaccination against SARS-CoV-2 did not result in adverse events or increase the number of antibodies and spike-specific T cells without having a significant positive or negative effect on the intrinsic quality of adaptive immune responses. ” the authors concluded. It is vital to note that we do not endorse hypervaccination as a strategy for adaptive immunity,” they added.

This story appeared in Ars Technica.

Esteban Ornes

Carolina Haskins

Andy Greenberg

Aarian Marshall

In Your Inbox: The Best and Strangest Stories from WIRED’s Iconic Archives

Violent Predator Network Extorts Children to Commit Acts of Abuse

Solar Agriculture Is Depleting the World’s Groundwater Reserves

Can Reddit, the web’s most trusted human forum, have its own IPO?

Battery-powered bikes: the benefits of riding a bike, without breaking a sweat

Esteban Ornes

Amy Paturel

Reece Rogers

Sachi Mulkey

Matt Reynolds

Emily Mullin

Jennifer Billock

Emily Mullin

More from WIRING

Reviews & Guides

© 2024 Condé Nast. All rights reserved. WIRED would possibly earn a portion of sales of products purchased through our site as part of our partner component partnerships with retailers. Curtains on this site may not be reproduced, distributed, transmitted, cached, or otherwise used unless with the prior written permission of Condé Nast. Ad Choices

Leave a Comment

Your email address will not be published. Required fields are marked *